Pharma major Eli Lilly has completed the technology transfer of multi-drug-resistant tuberculosis (MDR-TB) drug cycloserine in India to Shasun Chemicals and Drugs.
Beginning in 2003, the effort included Eli Lilly donating manufacturing technology and know-how for two antibiotics to pharmaceutical manufacturers in China, India, Russia and South Africa — all MDR-TB hot spots, the company said in a statement.
“In India, the technology transfer of second line drug cycloserine has been completed with Shasun Chemicals and Drugs,” it added. Commenting on the initiative, Lilly’s Chairman, President and Chief Executive Officer John Lechleiter said: “I am very proud of the fact that we looked beyond the question of can we supply these medicines..., it’s been an extraordinary story and an extraordinary accomplishment.”
Eli Lilly and Company had started transferring its manufacturing technology and know—how for capreomycin and cycloserine free of charge to seven manufacturers after consulting with global TB experts.
